Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).
- Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): Complete Statistical AnalysisIndependent statistical analysis of Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GeniProIndependent statistical analysis of Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: Complete Statistical AnalysisIndependent statistical analysis of Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GeparSixtoIndependent statistical analysis of GeparSixto (NCT01426880), a randomized phase 2/3 trial evaluating addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer.
- GETUGV04Independent statistical analysis of A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GioTagIndependent statistical analysis of the GioTag study of afatinib followed by osimertinib in EGFR mutation-positive non-small-cell lung cancer, including its single-arm design, treatment-duration endpoint, planned analysis, and statistical interpretation.
- Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…
- Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: Complete Statistical AnalysisIndependent statistical analysis of Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GRABM-LIndependent statistical analysis of GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GRAY-BIndependent statistical analysis of GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GRECCAR 2Independent statistical analysis of GRECCAR 2, a randomized phase 3 trial comparing local rectal excision with total mesorectal excision in rectal neoplasms, including its composite 24-month primary endpoint and planned statistical interpretation.
- GRECCAR-4Independent statistical analysis of GRECCAR-4, a randomized phase 2 trial evaluating a tailored strategy for locally advanced rectal carcinoma, including its design, R0 resection endpoint, planned statistical analysis, and interpretation.
- Green Tea and Reduction of Breast Cancer Risk: Complete Statistical AnalysisIndependent statistical analysis of Green Tea and Reduction of Breast Cancer Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00917735).
- Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery: Complete Statistical AnalysisIndependent statistical analysis of Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: Complete Statistical AnalysisIndependent statistical analysis of GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GSK1120212+GSK2141795 for Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of GSK1120212+GSK2141795 for Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01958112).
- Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- HALO Patient Registry: Ablation of Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of HALO Patient Registry: Ablation of Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00848237).
- HALT-DIndependent statistical analysis of Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Haplo/CordIndependent statistical analysis of Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: Complete Statistical AnalysisIndependent statistical analysis of Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01050764).
- HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02232243).
- HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849588).
- HCW9218 in Select Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of HCW9218 in Select Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05322408).
- HD10Independent statistical analysis of HD10, a 150-patient clinical trial evaluating dual-point PET acquisition in early stage Hodgkin lymphoma patients with bulky lesions, with event-free survival assessed at 1 year.
- HDIL2/EmendIndependent statistical analysis of Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Health Gatherings – For Your Health After Cancer: Complete Statistical AnalysisIndependent statistical analysis of Health Gatherings - For Your Health After Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03344757).
- Health Literacy Interventions to Overcome Disparities in CRC Screening: Complete Statistical AnalysisIndependent statistical analysis of Health Literacy Interventions to Overcome Disparities in CRC Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02360605).
- HEROIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin’s Lymphoma or Central Nervous System (CNS) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…